The FDA approval for the individual patient trial application is a significant regulatory milestone, potentially leading to positive sentiment around the stock. The promising early results from the trial could further boost investor confidence. Additionally, the $5 million share repurchase program indicates that the company believes its stock is undervalued, which is likely to positively impact the stock price in the short term.